DOL.TO 1.05CRCL 0CLS.TO 49.22ZGI.TO -0.74XMW.TO 0.11XMU.TO 0.21MSFT 23.25
Daily Stock Opinions and Ratings
Stockchase Opinions

Jim LebenthalIshares Nasdaq BiotechnologyIBBBUYJul 12, 2024

The sector has been up. It makes sense because biotechs do well as rates fall; these companies finance long-duration trials then marketing.

Jim LebenthalJim Lebenthal
Unknown
Unlock Rating
$145.32

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

Ishares Nasdaq Biotechnology(IBB)

Feb 26, 2025

He likes big pharma with AbbVie his favourite name. Pipelines are starting to fill, and if rates hold and R&D gets cheaper, these stocks will continue to work.

Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$137.48

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
BUY

Ishares Nasdaq Biotechnology(IBB)

Jul 19, 2024

He prefers to own individual names, but you need to own biotech, especially if there's a change in Washington (less regulation). It's very sensitive to interest rates, which will likely decline.

Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge Capital
No
Unlock Rating
$143.99

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
HOLD

Ishares Nasdaq Biotechnology(IBB)

Jun 07, 2023

He bought this, expecting biotech to break out, but it's been deeply disappointing. It hasn't worked yet.

Photo of Joe TerranovaJoe Terranova
Owned
Unlock Rating
$128.83

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
BUY

Ishares Nasdaq Biotechnology(IBB)

Oct 28, 2022
The IBB has never had two down years in a row, except this and last year. It's having its best month since June 2021.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital PartnersUnlock Rating
$128.09

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
BUY

Ishares Nasdaq Biotechnology(IBB)

Aug 19, 2022
He likes biotech, focusing on longevity research. Better than owning a single biotech stock where you can lose 80% just on negative research findings. It's completely random--you have no idea what the outcome will be on these biotech products. Might as well own IBB and lessen risk.
Photo of Kevin O'LearyKevin O'Leary
Owned
Unlock Rating
$128.34

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
WATCH

Ishares Nasdaq Biotechnology(IBB)

May 13, 2022
He sold IBB last month, though he owns a lot of Regeneron (for its fundamentals) in the biotech space. You need to own individual names, not the macro in biotechs. But he could re-enter IBB when the time is right.
Photo of Rob Sechan, Managing Partner, New Edge CapitalRob Sechan, Managing Partner, New Edge Capital
No
Unlock Rating
$113.19

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
DON'T BUY

Ishares Nasdaq Biotechnology(IBB)

Feb 03, 2022
IBB vs. XLV XLV has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$130.96

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
BUY ON WEAKNESS

Ishares Nasdaq Biotechnology(IBB)

Dec 31, 2021
IBB gives him exposure to Moderna, its largest holding, and yet there's no single-company risk here. Biotechs have been under a lot of pressure this year, so he sees an opportunity (past of the pressure has been from shorting) if you're patient. He likes the future of biotech.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
$153.75

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB)

Jun 24, 2021
(A Top Pick Jul 09/20, Up 14%) Still likes it, but took profits as the valuation was getting expensive, plus the shift from growth to value. Long term, lots of tailwinds.
Photo of Stan WongStan Wong
No
Unlock Rating
$161.70

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB)

May 19, 2021
(A Top Pick Jul 09/20, Up 6%) Sold in February, as he saw the writing on the wall with the rotation away from growth. Not cheap at 28x. Long-term, makes a lot of sense. Aging population, growing middle class in emerging markets will keep demand up.
Photo of Stan WongStan Wong
No
Unlock Rating
$148.78

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
BUY

Ishares Nasdaq Biotechnology(IBB)

Jul 13, 2020

Healthcare sector outlook The sector has had a great bounce since March lows. A good way to play the COVID vaccine race. IBB is the best-known biotech ETF, but he does the XBI, because it's equal-weighted. XBI has had a great bounce. It's a great sector with reasonable valuations. The race for a COVID vaccine is a tailwind, of course. Biotech is a slow-growth area, which benefit from interest rates staying very low for the long term.

Photo of John ZechnerJohn Zechner
No
Unlock Rating
$141.99

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
TOP PICK

Ishares Nasdaq Biotechnology(IBB)

Jul 09, 2020
Growth of biotech is expected to explode in a post-pandemic world. Longer term, aging population and growth of middle class are tailwinds. 27 bps expense ratio. Yield is 0.22%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$140.06

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
HOLD

Ishares Nasdaq Biotechnology(IBB)

Jan 02, 2020
A very good biotech ETF. If you have it and you like it, stay with it. See what percentage of your portfolio it comprises. For a sector play, don't go above 5-6% of your portfolio. You want to invest in it, not day trade it with every move.
Photo of John HoodJohn HoodUnlock Rating
$119.89

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s
PAST TOP PICK

Ishares Nasdaq Biotechnology(IBB)

Oct 18, 2019
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$102.27

Stock price when the opinion was issued

$172.18

As of May 29, 2026. Market Open.

E.T.F.'s

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DELL 103.86$420.91
MSFT 23.25$450.24
AWK 0.92$123.27
DELL 103.86$420.91
IGV 5.98$101.66

Today's Top Picks

DOL.TO 1.05$176.3
CRCL 0$
CLS.TO 49.22$533.01
ZGI.TO -0.74$57.31
XMW.TO 0.11$59.3

Popular Articles

Latest Sell Signals

COST -38.88$956.32
CAT -11.8$875.87
T.TO 0.03$17.31
BB.TO 0.25$12.36
GEV -27.68$968.32

Most Recent Experts

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Bryn Talkington

Bryn Talkington

Requisite Capital Management

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica